Rocket Pharma rises as FDA approves gene therapy

What: Rocket Pharma's stock has risen after the FDA approved its gene therapy treatment for a rare genetic disorder.
Why: The approval is seen as a significant milestone for the company, which has been working on the treatment for several years.
Signal: The FDA's approval is a strong signal to investors that the treatment is safe and effective.
Target: The company is now targeting commercialization of the treatment, which is expected to bring in significant revenue.
Risk: However, the company still faces risks related to manufacturing and regulatory compliance.